CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).

被引：0
|
作者：
Chiorean, E. Gabriela
Von Hoff, Daniel D.
Ervin, Thomas J.
Arena, Francis P.
Infante, Jeffrey R.
Bathini, Venu Gopal
Wood, Tina Evans
Mainwaring, Paul N.
Muldoon, Robert T.
Clingan, Philip R.
Kunzmann, Volker
Ramanathan, Ramesh K.
Tabernero, Josep
Goldstein, David
Ko, Amy
Lu, Brian
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA
[3] Florida Canc Specialists, Englewood, FL USA
[4] Arena Oncol Associates, Lake Success, NY USA
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] Tennessee Oncol, Nashville, TN USA
[7] Univ Massachusetts, Sch Med, Canc Ctr Excellence, Worcester, MA USA
[8] UAB Comprehens Canc Ctr, Birmingham, AL USA
[9] Mater Private Ctr Haematol & Oncol, South Brisbane, Australia
[10] Genesis Canc Ctr, Hot Springs, AR USA
[11] Southern Med Day Care Ctr, Wollongong, NSW, Australia
[12] Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[13] Vall dHebron Univ Hosp, Barcelona, Spain
[14] Prince Wales Hosp, Sydney, NSW, Australia
[15] Celgene Corp, Summit, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4058
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Interim results of a multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).
    Lacy, Jill
    Portales, Fabienne
    Hammel, Pascal
    Cid, Roberto A. Pazo
    Mozo, Jose Luis Manzano
    Kim, Edward Jae-hoon
    Dowden, Scot D.
    Borg, Christophe
    Sastre, Javier
    Bathini, Venu Gopal
    Terrebonne, Eric
    Lopez-Trabada, Daniel
    Rivera, Fernando
    Asselah, Jamil
    Damiani, Azzurra
    Hwang, Jimmy J.
    Ong, Teng Jin
    Nydam, Thom
    Li, Jack Shiansong
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [32] Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses
    Tempero, M. A.
    Reni, M.
    Riess, H.
    O'Reilly, E. M.
    Krishnamurthi, S.
    Osterlund, P.
    Ales-Diaz, I. C.
    Milella, M.
    Siena, S.
    Tabernero, J.
    Van Cutsem, E.
    Philip, P. A.
    Goldstein, D.
    Berlin, J. D.
    Li, M.
    Ferrara, S.
    Le Bruchec, Y.
    McGovern, D.
    Biankin, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P plus Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.
    Reni, Michele
    Riess, Hanno
    O'Reilly, Eileen Mary
    Park, Joon Oh
    Hatoum, Hassan
    Saez, Berta Laquente
    Salminen, Tapio
    Oettle, Helmut
    Lopez, Rafael
    Dowden, Scot D.
    Karthaus, Meinolf
    Tabernero, Josep
    Van Cutsem, Eric
    Philip, Philip Agop
    Goldstein, David
    Berlin, Jordan
    Tempero, Margaret A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT).
    Tempero, Margaret A.
    Cardin, Dana Backlund
    Biankin, Andrew
    Goldstein, David
    Moore, Malcolm
    O'Reilly, Eileen Mary
    Philip, Philip Agop
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Li, Mingyu
    Lu, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Impact of nab-paclitaxel (nab-P) plus gemcitabine (G) vs gemcitabine alone on Karnofsky performance status (KPS) in metastatic pancreatic cancer patients with good or poor performance status at baseline: A post-hoc analysis of the MPACT trial
    Chiorean, E. G.
    Wan, Y.
    Whiting, S.
    Botteman, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S450 - S450
  • [36] SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
    Hidalgo, Manuel
    Plaza, Carlos
    Musteanu, Monica
    Illei, Peter
    Brachmann, Carrie B.
    Heise, Carla
    Pierce, Daniel
    Lopez-Casas, Pedro P.
    Menendez, Camino
    Tabernero, Josep
    Romano, Alfredo
    Wei, Xinyu
    Lopez-Rios, Fernando
    Von Hoff, Daniel D.
    CLINICAL CANCER RESEARCH, 2015, 21 (21) : 4811 - 4818
  • [37] nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
    Tehfe, Mustapha
    Dowden, Scot
    Kennecke, Hagen
    El-Maraghi, Robert
    Lesperance, Bernard
    Couture, Felix
    Letourneau, Richard
    Liu, Helen
    Romano, Alfredo
    ADVANCES IN THERAPY, 2016, 33 (05) : 747 - 759
  • [38] Efficacy, Safety and Pharmacokinetics (PK) of Weekly nab-paclitaxel (P) Plus Gemcitabine (G) in Japanese Patients (pts) With Metastatic Pancreatic Cancer (MPC): Phase I/II Trial
    Kasuga, A.
    Ueno, H.
    Ikeda, M.
    Ueno, M.
    Mizuno, N.
    Ioka, T.
    Omuro, Y.
    Nakajima, T. E.
    Furuse, J.
    PANCREAS, 2014, 43 (08) : 1374 - 1374
  • [39] nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
    Mustapha Tehfe
    Scot Dowden
    Hagen Kennecke
    Robert El-Maraghi
    Bernard Lesperance
    Felix Couture
    Richard Letourneau
    Helen Liu
    Alfredo Romano
    Advances in Therapy, 2016, 33 : 747 - 759
  • [40] Efficacy and safety of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in Chinese patients (Pts) with metastatic adenocarcinoma of the pancreas (MPC): A phase II study
    Yu, X.
    Shen, L.
    Hao, J.
    Wang, L.
    Pan, H.
    Han, G.
    Xu, J.
    Zhang, Y.
    Yang, S.
    Ying, J.
    Li, M.
    Begic, D.
    Lu, B.
    Xu, R.
    ANNALS OF ONCOLOGY, 2015, 26 : 66 - 67
12345